The Various Clinical and Therapeutic Particularities of ET According to JAK2 or CALR Molecular Subtypes.
The Various Clinical and Therapeutic Particularities of ET According to JAK2 or CALR Molecular Subtypes.
| JAK2V617F-mutated ET | CALR-mutated ET | ||
|---|---|---|---|
| Age, sex | Older | Younger, M>F | |
| Blood counts | Hemoglobin | Higher | Lower |
| Platelet | Lower | Higher | |
| White blood count | Higher | Lower | |
| Serum erythropoietin level | Lower | Higher | |
| Thrombotic risk | Higher | Lower | |
| Polycythemic risk | Cumulative risk 29% at 15 years | No transformation to PV | |
| MF transformation risk | Conflicting results | ||
| Overall survival (OS) | Long-term OS similar to that in CALR-mutated ET | Long-term OS similar to that in JAK2V617F-mutated ET | |
| Treatment implications | ET patients with CALR mutations are at a lower risk of thrombotic complications compared to those with JAK2 mutations; however, recommendations regarding modifications of current treatment based on mutation status have not been developed yet | ||